HomeNewsWorld NewsBiogen will pay $7.3 billion to acquire Reata Pharmaceuticals, the owner of a rare-disease treatment with the potential to be a blockbuster.

Biogen will pay $7.3 billion to acquire Reata Pharmaceuticals, the owner of a rare-disease treatment with the potential to be a blockbuster.

July 29, 2023

Biogen will pay $7.3 billion to acquire Reata Pharmaceuticals, the owner of a rare-disease treatment with the potential to be a blockbuster.

Leave a Reply

Your email address will not be published. Required fields are marked *

Disclaimer:

  • Trading foreign exchange on margin carries a high level of risk, and may not be suitable for all investors. The high degree of leverage can work against you as well as for you. Before deciding to invest in foreign exchange you should carefully consider your investment objectives, level of experience, and risk appetite. No information or opinion contained on this site should be taken as a solicitation or offer to buy or sell any currency, equity or other financial instruments or services. Past performance is no indication or guarantee of future performance. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you can afford to take the high risk of losing your money

Copyright: © 2023 iSeekFX. All Rights Reserved.